Blue Cross Blue Shield/Blue Care Network of Michigan Medication Authorization Request Form



Nonprofit corporations and independent licensees of the Blue Cross and Blue Shield Association

This form is to be used by participating physicians to obtain coverage for **drugs covered under the medical benefit**. For <u>commercial members only</u>, please complete this form and submit via fax to 1-877-325-5979. If you have any questions regarding this process, please contact BCBSM Provider Relations and Servicing or the Medical Drug Helpdesk at 1-800-437-3803 for assistance.

PATIENT INFORMATION	PHYSICIAN INFORMATION
Name	Name
ID Number	Specialty
D.O.B.	Address
Diagnosis	City /State/Zip
Drug Name	Phone: Fax:
Dose and Quantity	NPI
Directions	Contact Person
Date of Service(s)	Contact Person Phone / Ext.
STEP 1: DISEASE STATE INFORMATION	
☐ Yes ☐ No If No, a prior authorization is not re	the FEP member within the health plan's geographic service a rea? equired through this process.
	ers that will be serviced by a provider within the health plan's geographic raphic service area, please contact the health plan for questions regarding
 Is this member's FEP coverage primary or secondary If primary, continue with questionset. If secondary, an authorization is not needed the determination of benefit and additional information. 	arough this process. Please contact the member's primary coverage for

	eria Ouestions: What is the patient's diagnosis? ☐ Treatment-Resistant Depression ☐ Other diagnosis (please specify):		
2.	Will Spravato be administered under the supervision of a health	care provider? Yes No	
3.	Will the patient's blood pressure be assessed prior to and after each administration? Yes No		
4.	Will the patient be monitored for sedation and dissociation for at least two hours after a dministration? Yes No		
5.	Will the patient be monitored for clinical worsening and emergence of suicidal thoughts and behaviors? Yes No		
6.	FEMALE Patient : Is the patient pregnant or is the patient of child bearing potential? □ Yes □ No *If YES, has the patient been or will the patient be a dvised about the risks for fetal harm? □ Yes □ No		
7.	Will Spravato be used in conjunction with an oral antidepressant? □ Yes □ No		
8.	Has the patient been on Spravato continuously for the last month , <u>excluding samples</u> ? Please select answer below:		
	NO – this is INITIATION of therapy, please answer the form. a. Was the patient's depression diagnosed using an appro *For more information about PHQ-9, please visit: https://www.uspreventiveservicestaskforce.org/Home/	ved scoring tool, such as the *PHQ-9? □ Yes □ No	
	b. Is the healthcare setting, pharmacy, and patient register	red with the REMS program? Yes No	
	c. Has the patient had an inadequate treatment response, of least TWO different antidepressants? ☐ Yes ☐	leveloped an intolerance to, or have a contraindication to at No	
Chart notes ar	a. Has the patient been evaluated for a positive response to the processing of all requests. Please add any other supports of the processing of all requests. Please add any other supports of the processing of the provided if the prescribing physician's significant to the physiciant to the physiciant to the prescribing physiciant to the physici	orting medical information necessary for our review (required)	
Request for exp	edited review: I certify that applying the standard review time frame may seriously jeopardize the life or he		
Physician's Na	•	Date	
Step 2: Checklist	☐ Form Completely Filled Out ☐ Provide chart notes	☐ Attach test results	
Step 3:	By Fax: BCBSM Specialty Pharmacy Mailbox	By Mail: BCBSM Specialty Pharmacy Program	

1-877-325-5979

Submit

P.O. Box 312320, Detroit, MI 48231-2320